Anti-androgen

DRUG3 trials

Sponsors

Radiation Therapy Oncology Group, University Health Network, Toronto

Conditions

AdvancedMetastaticProstate CancerRecurrentSalivary Gland Cancer

Phase 3

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Active, not recruitingNCT01368588

Radiation Therapy Oncology GroupProstate Cancer

Start: 2011-07-01End: 2031-07-01Updated: 2026-05-08

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

CompletedNCT01546987

Radiation Therapy Oncology GroupProstate Cancer

Start: 2012-05-01End: 2025-09-04Updated: 2026-03-06

Unknown Phase

A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

CompletedNCT02069730

University Health Network, TorontoAdvanced, Metastatic, Recurrent +1

Start: 2014-06-30End: 2023-06-30Updated: 2026-01-08

Related Papers

Abstract P154: Genomic profiling and matched therapy for recurrent or metastatic salivary gland neoplasms. Results from the matched cohort of the GEMS-001 clinical trial

Molecular Cancer Therapeutics2021-12-011 citations

Molecular profiling and targeted agents in recurrent, metastatic salivary gland tumor (R/M SGT) patients (pts) treated at two academic centers.

Journal of Clinical Oncology2021-05-203 citations

Moderately Hypofractionated Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Prostate Cancer: Five-Year Toxicity Results From a Prospective Phase I/II Trial

Frontiers in Oncology2020-08-214 citations

Recurrent or metastatic salivary gland tumor (MSGT) patients treated with selinexor, a first in class selective exportin-1 (XPO1) inhibitor.

Journal of Clinical Oncology2020-05-201 citations

Genomic profiling and matched therapy for recurrent or metastatic malignant salivary gland tumors

Annals of Oncology2018-10-01